Maureen Hillenmeyer, Hexagon Bio CEO
September 15, 2020 03:57 PM EDTUpdated September 30, 08:13 AM
Financing
R&D
AI

Us­ing AI to se­quence fun­gi genomes for can­cer treat­ments, Hexa­gon Bio nets $47M in Se­ries A

Max Gelman

Senior Editor

A Stan­ford spin­out ex­plor­ing how fun­gi can be se­quenced to dis­cov­er new med­i­cines in on­col­o­gy and in­fec­tious dis­eases now has sig­nif­i­cant­ly more cash to do …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Rev­o­lu­tion Med­i­ci­nes' KRAS drug shows po­ten­tial in ear­ly cut of lung can­cer da­ta

France stops Val­neva's chikun­gun­ya vac­cine roll­out in over 65s af­ter safe­ty is­sue

Ex­clu­sive: Can AI re­place an­i­mal test­ing? A new biotech launch­es to find out

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

Eu­ro­pean reg­u­la­tors rec­om­mend new drugs from Ver­tex, Am­gen and Jazz 

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times